Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors

Prostate

Volumn 69, Issue 10, 2009, Pages 1034-1044

  Kela, Itai ^a   Harmelin, Alon ^a   Waks, Tova ^a   Orr Urtreger, Avi ^b   Domany, Eytan ^a   Eshhar, Zelig ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Gene expression profiles; Interspecies comparison; Microarray analysis; Prostate cancer

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL CYCLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; MALE; MICRODISSECTION; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SPECIES COMPARISON; TISSUE MICROARRAY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CANCER STAGING; COMPARATIVE STUDY; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SPECIES DIFFERENCE; TRANSGENIC MOUSE;

DEATH RECEPTOR 3; TNFRSF25 PROTEIN, MOUSE;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM STAGING; PHENOTYPE; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; SPECIES SPECIFICITY;

EID: 67449135819     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20950     Document Type: Article

References (49)

1. Neal DE, Donovan JL. Prostate cancer: To screen or not to screen? Lancet Oncol 2000;1(1):17-24.
2. Greenberg NM, DeMayo FJ, Finegold M, Medina D, Tilley W, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci 1995; 92:3439-3443.
3. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55(3):219-237. (Pubitemid 36532401)
4. Martiniello-Wilks R, Dane A, Mortensen E, Jeyakumar G, Wang XY, Russell PJ. Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Anticancer Res 2003;23(3B):2633-2642. (Pubitemid 36897137)
5. Greenberg NM, DeMayo FJ, Finegold M, Medina D, Tilley W, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci 1995; 92:3439-3443.
6. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: It is not only the cancer cell's fault. Endocr Relat Cancer 2002;9(1):61-73. (Pubitemid 34298364)
7. Cindolo L, Cantile M, Vacherot F, Terry S, de la Taille A. Neuroendocrine differentiation in prostate cancer: From lab to bedside. Urol Int 2007;79(4):287-296. (Pubitemid 350136512)
8. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007;14(3):531-547. (Pubitemid 350074046)
9. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56(18):4096-4102. (Pubitemid 26304996)
10. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57(21):4687-4691. (Pubitemid 27468967)
11. Wikstrom P, Lindahl C, Bergh A. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate 2005;62(2):148-164. (Pubitemid 40096781)
12. Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, Mineva ND, Kaplan-Lefko PJ, Foster BA, Cook BP, Dufault MR, Cao X, Wang CJ, Teicher BA, Klinger KW, Greenberg NM, Madden SL. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate 2007;67(1): 83-106. (Pubitemid 46013470)
13. Deng MY, Wang H, Ward GB, Beckham TR, McKenna TS. Comparison of six RNA extraction methods for the detection of classical swine fever virus by real-time and conventional reverse transcription-PCR. J Vet Diagn Invest 2005;17(6):574-578. (Pubitemid 41666907)
14. Burgemeister R, Gangnus R, Haar B, Schutze K, Sauer U. High quality RNA retrieved from samples obtained by using LMPC (laser microdissection and pressure catapulting) technology. Pathol Res Pract 2003;199(6):431-436. (Pubitemid 36974831)
15. Marcelo Blatt SW. Eytan Domany. Superparamagnetic clustering of data. Phys Rev Lett 1995;76(18):3251-3254.
16. Tsafrir D, Tsafrir I, Ein-Dor L, Zuk O, Notterman DA, Domany E. Sorting points into neighborhoods (SPIN): Data analysis and visualization by ordering distance matrices. Bioinformatics 2005;21(10):2301-2308.
17. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39(1):41-51. (Pubitemid 46026500)
18. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003;63(14):3877-3882. (Pubitemid 36917897)
19. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004;101(3):811-816. (Pubitemid 38121040)
20. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61(16):5974-5978. (Pubitemid 32762523)
21. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1(2):203-209. (Pubitemid 41039166)
22. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412(6849):822-826. (Pubitemid 32801464)
23. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22(14):2790-2799. (Pubitemid 41079896)
24. Varambally S,YuJ,LaxmanB, Rhodes DR, Mehra R, Tomlins SA, Shah RB, ChandranU, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8(5):393-406. (Pubitemid 41579834)
25. Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007;67(22):10657-10663. (Pubitemid 350145890)
26. Margiotti K, Wafa LA, Cheng H, Novelli G, Nelson CC, Rennie PS. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells. Mol Cancer 2007;6:38. (Pubitemid 47045979)
27. Hu Y, Ippolito JE, Garabedian EM, Humphrey PA, Gordon JI. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002;277(46):44462-44474. (Pubitemid 36157881)
28. Koh T, Yokota J, Ookawa K, Kina T, Koshimura K, Miwa S, Ariyasu T, Yamada H, Osaka M, Haga H, Hitomi S, Sugiyama T, Takahashi R. Alternative splicing of the neurofibromatosis 1 gene correlates with growth patterns and neuroendocrine properties of human small-cell lung-carcinoma cells. Int J Cancer 1995;60(6):843-847.
29. Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, Inai K, Kohno N, Nakamura Y. Gene expression profiles of small-cell lung cancers: Molecular signatures of lung cancer. Int J Oncol 2006;29(3):567-575.
30. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA,Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, BagnatoM, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40(3):316-321. (Pubitemid 351311772)
31. Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007;26(31):4590-4595. (Pubitemid 47037047)
32. Sun CQ, Arnold R, Fernandez-Golarz C, Parrish AB, Almekinder T,HeJ,HoSM, Svoboda P, Pohl J, Marshall FF, Petros JA.Human beta-defensin-1, a potential chromosome 8p tumor suppressor: Control of transcription and induction of apoptosis in renal cell carcinoma. Cancer Res 2006;66(17):8542-8549. (Pubitemid 44449167)
33. Barash B, Friedman N. A simple hyper-geometric approach for discovering putative transcription factor binding sites. Lecture Notes Comput Sci 2001;249:278-293. (Pubitemid 33322589)
34. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41(6):858-887. (Pubitemid 40461690)
35. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415(6871):530-536.
36. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005;65(10):4059-4066.
37. Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Cremoux P, de La Rochefordiere A, Salmon R, Dorval T, Thiery JP, Couturier J, Radvanyi F, Domany E, Sastre-Garau X. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 2005;24(47):7094-7104. (Pubitemid 41573638)
38. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8(8):816-824. (Pubitemid 34887245)
39. Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006; 98(19):1420-1424. (Pubitemid 44530719)
40. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. Decreased Ecadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54(14):3929- 3933. (Pubitemid 24241218)
41. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13(23):7003-7011.
42. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR, Balmain A. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172(1):236-246.
43. Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, Greenberg NM, Smith GJ. Origin of androgeninsensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007; 9(11):938-950. (Pubitemid 350086439)
44. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008;452(7187):553-563.
45. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2(2):70-75. (Pubitemid 29259935)
46. Bethel CR, Bieberich CJ. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model. Prostate 2007;67(16):1740-1750. (Pubitemid 350228726)
47. Steiner MS. High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction. World J Urol 2003;21(1):15-20. (Pubitemid 44175291)
48. Jiang D, Srinivasan A, Lozano G, Robbins PD. SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene 1993; 8(10):2805-2812. (Pubitemid 23279109)
49. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, LeeWH, Marsilio E, Paucha E. DM L. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988;54(2):275-283. (Pubitemid 18188759)